The effect of Plasmapheresis on hypoxia in patients suffering from COVID-19
Phase 3
Recruiting
- Conditions
- Corona virus (Covid-19).J12.81Pneumonia
- Registration Number
- IRCT20220517054899N1
- Lead Sponsor
- Birjand University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Definitive diagnosis of Covid-19 based on taking a sample from the pharynx and PCR laboratory confirmation
Lung involvement more than 50%
SPO2 levels below 80% without oxygen or below 88% with oxygen or IL above 10 or ferritin above 1500
Patients who have not responded to other Covid-19 treatments
Age over 18 years and consent to participate in the study
Exclusion Criteria
History of albumin sensitivity
Heparin allergy who cannot receive heparin as an anticoagulant during plasmapheresis
Patients with hypocalcemia (citrate used in the plasmapheresis process exacerbates hypocalcemia)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Percentage of blood oxygen saturation (SPO2). Timepoint: On days zero (before the intervention), days one, three, five and seven after the intervention. Method of measurement: Pulse oximeter Bitmos Gmbh made in Germany.;Arterial blood oxygen pressure in the analysis of blood gases Pao2. Timepoint: On days zero (before the intervention), days one, three, five and seven after the intervention. Method of measurement: Blood sample to measure blood gases.
- Secondary Outcome Measures
Name Time Method Duration of hospitalization of the patient. Timepoint: End of hospitalization or death of the patient. Method of measurement: By day.;C-reactive protein (CRP) Factor. Timepoint: On days zero (before the intervention), days one, three, five and seven after the intervention. Method of measurement: Blood Test Prestige 24i machine made in Japan.